Further phenotypic and functional characterization of the CD4+ T cells involved in the priming of the anti-tumor immune response following therapeutic treatment revealed that while untreated tumor-bearing mice had in their spleen and tumor-draining lymph nodes IL-4-secreting TH2-type cells, treated mice displayed a mixed TH1- and TH2-type of response with a great percentage of cells secreting IFNγ [46,47]. The gene discussed is IL4; the disease is neoplasm.